Kombiglyze XR (saxagliptin + metformin XR) - AstraZeneca
AstraZeneca: Annual Report 2013 (AstraZeneca) - Mar 21, 2014 - Anticipated composition of matter patent expiry in US in 2023; Anticipated composition of matter patent expiry in EU in 2026 
Anticipated patent expiry Diabetes
http://www.astrazeneca-annualreports.com/2013/_assets/pdfs/AstraZeneca_Annual_Report_2013.pdf
 
Mar 21, 2014
 
.
 
5b44d313-df5e-4d47-ab66-1c351d8ae7ed.jpg

47ea881f-a7d5-4695-bf90-32b0c13f019d.jpg